"Antithrombins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
| Descriptor ID |
D000991
|
| MeSH Number(s) |
D27.505.519.389.745.800.449 D27.505.954.502.119.500
|
| Concept/Terms |
Antithrombins- Antithrombins
- Direct Thrombin Inhibitors
- Thrombin Inhibitors, Direct
- Direct Antithrombins
- Antithrombins, Direct
|
Below are MeSH descriptors whose meaning is more general than "Antithrombins".
Below are MeSH descriptors whose meaning is more specific than "Antithrombins".
This graph shows the total number of publications written about "Antithrombins" by people in this website by year, and whether "Antithrombins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antithrombins" by people in Profiles.
-
Recommendations on Monitoring and Replacement of Antithrombin, Fibrinogen, and Von Willebrand Factor in Pediatric Patients on Extracorporeal Membrane Oxygenation: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference. Pediatr Crit Care Med. 2024 Jul 01; 25(7 Suppl 1):e35-e43.
-
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2023 08; 89(8):2396-2406.
-
Exploring the Role of Antithrombin in Nephrotic Syndrome-Associated Hypercoagulopathy: A Multi-Cohort Study and Meta-Analysis. Clin J Am Soc Nephrol. 2023 02 01; 18(2):234-244.
-
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. Thromb Haemost. 2022 Sep; 122(9):1573-1583.
-
Bivalirudin or Unfractionated Heparin for Anticoagulation in Pediatric Patients on Continuous Flow Ventricular Assist Device Support: Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022 10 01; 23(10):e465-e475.
-
Bivalirudin for the prevention of hepatic artery thrombosis in pediatric liver transplantation. Pediatr Transplant. 2021 Nov; 25(7):e14068.
-
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021 05; 19(5):1259-1270.
-
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. Ann Neurol. 2021 03; 89(3):444-458.
-
Low antithrombin levels in neonates and infants undergoing congenital heart surgery result in more red blood cell and plasma transfusion on cardiopulmonary bypass. Transfusion. 2020 12; 60(12):2841-2848.
-
Anticoagulation of Impella with a Bivalirudin Purge Solution. ASAIO J. 2020 Sep/Oct; 66(9):e117-e120.